CN103717229A - 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 - Google Patents
以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 Download PDFInfo
- Publication number
- CN103717229A CN103717229A CN201280027034.9A CN201280027034A CN103717229A CN 103717229 A CN103717229 A CN 103717229A CN 201280027034 A CN201280027034 A CN 201280027034A CN 103717229 A CN103717229 A CN 103717229A
- Authority
- CN
- China
- Prior art keywords
- extract
- piper longum
- diabetes
- obesity
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 235000019510 Long pepper Nutrition 0.000 title claims abstract description 63
- 210000003205 muscle Anatomy 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 240000003455 Piper longum Species 0.000 title claims description 62
- 208000008589 Obesity Diseases 0.000 title claims description 32
- 235000020824 obesity Nutrition 0.000 title claims description 32
- 235000013399 edible fruits Nutrition 0.000 title claims description 26
- 239000004480 active ingredient Substances 0.000 title claims description 10
- 230000001965 increasing effect Effects 0.000 title abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 46
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 42
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 28
- 102000004877 Insulin Human genes 0.000 claims abstract description 21
- 108090001061 Insulin Proteins 0.000 claims abstract description 21
- 229940125396 insulin Drugs 0.000 claims abstract description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 20
- 239000008103 glucose Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 20
- 230000037396 body weight Effects 0.000 claims abstract description 19
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 18
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 7
- 230000007246 mechanism Effects 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 7
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 7
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 6
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims 3
- 239000013589 supplement Substances 0.000 claims 2
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000035924 thermogenesis Effects 0.000 abstract description 2
- 230000003579 anti-obesity Effects 0.000 abstract 2
- 240000002286 Piper retrofractum Species 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- 229960001031 glucose Drugs 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000010171 animal model Methods 0.000 description 11
- 101150073133 Cpt1a gene Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000003178 anti-diabetic effect Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000007918 intramuscular administration Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 101000939438 Homo sapiens Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WHAAPCGHVWVUEX-UHFFFAOYSA-N Piperlonguminine Natural products CC(C)CNC(=O)C=CC=CC1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-UHFFFAOYSA-N 0.000 description 4
- VOZJBFJHMHRLDN-ZUVMSYQZSA-N methyl (2e,4e)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate Chemical compound COC(=O)\C=C\C=C\C1=CC=C2OCOC2=C1 VOZJBFJHMHRLDN-ZUVMSYQZSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- VABYUUZNAVQNPG-UHFFFAOYSA-N Piperlongumine Natural products COC1=C(OC)C(OC)=CC(C=CC(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-UHFFFAOYSA-N 0.000 description 3
- VABYUUZNAVQNPG-BQYQJAHWSA-N Piplartine Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-BQYQJAHWSA-N 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- VOZJBFJHMHRLDN-UHFFFAOYSA-N Methylpiperat Natural products COC(=O)C=CC=CC1=CC=C2OCOC2=C1 VOZJBFJHMHRLDN-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000758706 Piperaceae Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 2
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- -1 gelinite Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 2
- 229940075559 piperine Drugs 0.000 description 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 2
- 235000019100 piperine Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WHAAPCGHVWVUEX-GGWOSOGESA-N (E,E)-Piperlonguminine Chemical compound CC(C)CNC(=O)\C=C\C=C\C1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-GGWOSOGESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000123330 Fomes fomentarius Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- FPMPOFBEYSSYDQ-AUVZEZIHSA-N Guineensine Chemical compound CC(C)CNC(=O)\C=C\C=C\CCCCCC\C=C\C1=CC=C2OCOC2=C1 FPMPOFBEYSSYDQ-AUVZEZIHSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- QMIWSRNEYNUYFE-WKOVGYJXSA-N N-Isobutyldeca-trans-2-trans-4-dienamide Natural products O=C(N[C@@H](CC)C)/C=C/C=C/CCCCC QMIWSRNEYNUYFE-WKOVGYJXSA-N 0.000 description 1
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 1
- RPOYGOULCHMVBB-ADDDGJNWSA-N Pipercide Chemical compound CC(C)CNC(=O)\C=C\C=C\CCCC\C=C\C1=CC=C2OCOC2=C1 RPOYGOULCHMVBB-ADDDGJNWSA-N 0.000 description 1
- DYIPBGULDOZWPD-UPZYHHBKSA-N Pipercide Natural products O=C(N[C@H](CC)C)/C=C/C=C/CCCC/C=C/c1cc2OCOc2cc1 DYIPBGULDOZWPD-UPZYHHBKSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- AHEYHYFMDFGWEG-FMQCLRLRSA-N Retrofractamide A Natural products O=C(N[C@@H](CC)C)/C=C/C=C/CC/C=C/c1cc2OCOc2cc1 AHEYHYFMDFGWEG-FMQCLRLRSA-N 0.000 description 1
- BPSWISYORIWKCT-FCGWLDPVSA-N Retrofractamide A Chemical compound CC(C)CNC(=O)\C=C\C=C\CC\C=C\C1=CC=C2OCOC2=C1 BPSWISYORIWKCT-FCGWLDPVSA-N 0.000 description 1
- RPOYGOULCHMVBB-FAZSMNIISA-N Retrofractamide B Natural products CC(C)CNC(=O)C=C/C=C/CCCCC=C/c1ccc2OCOc2c1 RPOYGOULCHMVBB-FAZSMNIISA-N 0.000 description 1
- PAXQNYHJDFKFEU-FIFLTTCUSA-N Retrofractamide C Chemical compound CC(C)CNC(=O)\C=C\CCCC\C=C\C1=CC=C2OCOC2=C1 PAXQNYHJDFKFEU-FIFLTTCUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- MAGQQZHFHJDIRE-VVKPDYKWSA-N cis-pellitorine Natural products C(C(C)C)NC(\C=C\C=CCCCCC)=O MAGQQZHFHJDIRE-VVKPDYKWSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- YMEOKCQRDKKTBN-UNRFKFNXSA-N guineensine Natural products O=C(N[C@@H](CC)C)/C=C/C=C/CCCCCC/C=C/c1cc2OCOc2cc1 YMEOKCQRDKKTBN-UNRFKFNXSA-N 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- DPCSPGOPQYRPCP-UHFFFAOYSA-N n-[4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]phenyl]acetamide Chemical compound C1CN(CCCN(C)C)CCN1C1=CC=C(NC(C)=O)C=C1 DPCSPGOPQYRPCP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- MAGQQZHFHJDIRE-BNFZFUHLSA-N pellitorine Chemical compound CCCCC\C=C\C=C\C(=O)NCC(C)C MAGQQZHFHJDIRE-BNFZFUHLSA-N 0.000 description 1
- MAGQQZHFHJDIRE-UHFFFAOYSA-N pellitorine Natural products CCCCCC=CC=CC(=O)NCC(C)C MAGQQZHFHJDIRE-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229950004889 piperamide Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- PAXQNYHJDFKFEU-UHFFFAOYSA-N retrofractamide-C Natural products CC(C)CNC(=O)C=CCCCCC=CC1=CC=C2OCOC2=C1 PAXQNYHJDFKFEU-UHFFFAOYSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种通过利用脂肪细胞的UCP活性产生的生热作用,改善抗肥胖及胰岛素抗性而对抗糖尿病及肌肉量增加与运动能力提升非常有效的食品及药物组合物,具体地说,涉及一种含有假荜拔(PiperretrofractumVahl.)提取物的组合物的新用途,也就是涉及一种通过减少体重及体脂肪而抗肥胖,通过降低血糖及血液中胰岛素改善胰岛素抗性而抗糖尿病,以及通过增加肌肉的能量源供给而使肌肉量增加和耐力增强在内的运动能力提升相关的食品组合物或药物组合物。
Description
技术领域
本发明涉及一种用于肥胖及糖尿病的预防与治疗、使肌肉量增加及运动能力提升的组合物,具体地说,涉及一种含有假荜拔(Piper retrofractum Vahl.)提取物的组合物的新用途。本发明提供了一种通过增强人体的生热作用而减少体重和体脂肪,通过降低人体的血糖与胰岛素水平而产生抗糖尿病功能,通过增加人体肌肉的能量源供给而使肌肉量增加及耐力增强在内的运动能力提升的功能性食品组合物或药物组合物。
背景技术
依据2010年经济合作与发展组织(OECD)的肥胖报告,韩国的成人肥胖率(BMI:30以上)为4%,30%表现为超重(BMI:25~30)。从世界范围看,肥胖人口达到了2亿5000万人,预计到2025年将达到3亿人以上。为了治疗肥胖,需采用通过使消耗的热量大于摄取热量从而消耗体内能量的方法。能够消耗体内能量的方法包括身体运动(exercise)和生热作用(thermogenesis)。现在,研发人员正在广泛研究通过一定强度以上的规则性运动而激活与运动相关的基因从而提高其效率的方案。生热作用就是,存在于线粒体中的运输蛋白的一种,即,解偶联蛋白(UCP,uncoupling protein),使蛋白质泄漏(proteinleak)增加并通过解偶联氧化(uncoupling oxidation),在不生成ATP的情况下产生热量。其中,UCP1存在于褐色脂肪组织(BAT,Brown adipose tissue)中,UCP2和UCP3存在于肌肉及脂肪组织中,它们的作用在于调节体内能量平衡。另外,肥胖人群的体内代谢状况与非肥胖人群相比,其脂肪代谢、糖代谢都不相同,这是由于胰岛素抗性(insulin resistance)使胰岛素不能正常发挥作用所导致的。持续性的胰岛素抗性最终会产生糖尿病,据报道,相当多的糖尿病患者都是因为肥胖而导致的。
目前开发的具有代表性的抗肥胖药物即诺美亭和赛尼可,具有导致嗓子干、晕眩症或者腹涨、脂肪便等多种副作用。最近,研发人员正在研究利用植物提取物等副作用小、安全性高的天然物研发一种不同于上述化学合成品的功能性食品。
因此,将在东南亚传统使用的药用植物中的假荜拔(Piper retrofractumVahl.)提取物长期让诱导肥胖的动物摄取后,对其体重及体脂肪量进行测定,结果发现上述指标均明显降低,研发人员猜想这是由脂肪细胞的UCP活性产生生热作用而导致的。
抗肥胖药用植物提取物中普洱茶组合物在10-2001-22510号,葫芦科植物提取物在10-2003-87280号,红参提取物在10-2006-115006号,海菊地上部分提取物在10-2007-56192号,棱子芹提取物在10-2006-38254号,葡萄树皮提取物在10-2007-82438号,决明子提取物在10-2006-91698中分别均有记载。
糖尿病大致分为1型糖尿病和2型糖尿病,主要发生在成人身上的2型糖尿病是由于胰岛素分泌降低和胰岛素抗性的原因造成的,其发病原因包括:胰岛素受体减少、细胞内胰岛素受体基质-1(IRS-1,insulin receptorsubstrate-1)缺乏、酪氨酸激酶(tyrosine kinase)活性度缺乏等多种因素。特别是,通常还会伴随多种代谢异常,它作为伴随有糖尿病性网膜症、肾衰竭、糖尿病足等并发症的慢性疾病中的一种,越是发达国家其发病率越高。
曲格列酮(troglitazone)、吡格列酮(pioglitazoe)及罗格列酮(rogigaltazone)等TZD系列药剂与其它治疗糖尿病的药剂相比,虽然其副作用较小,但是它们是到目前为止公认为具有肝毒性及导致肥胖等副作用的药物。
最近,研发人员正在研究利用植物提取物等副作用小、安全性高的天然物研发一种与上述化学合成品不同的功能性食品。
白桦茸子实体提取物的抗糖尿病效果在10-2005-36879号,桤木提取物的抗糖尿病效果在10-2002-48813号,木蹄层孔菌提取物的抗糖尿病效果在10-2003-69748号,桑叶提取物的抗糖尿病效果在10-2004-82926号中分别均有记载。
对于超重人群、肥胖人群或者虽然是正常体重但体脂肪量较高的人群,可以通过增加肌肉量并减少体脂肪对糖尿病、高血压等代谢综合症进行预防和治疗。肌肉量的增加会导致基础代谢能量的增加,可以防止减肥出现溜溜球效应,从而可以有效地进行减肥。为了增加肌肉量,可以通过运动、饮食疗法或使用提高运动能力的辅助剂(ergogenic aids)。现在,不论是东方还是西方,都正在进行与提高运动能力的功能性食品相关的研究。另外,对于包括类固醇、咖啡因、碳酸氢钠及柠檬酸钠等化学性化合物在内的辅助剂,虽然服用超过一定量可以显著增加运动能力,但是上述药物具有致命性的副作用,最终会给健康带来危害。
具体地说,作为肌肉的能量源,为了将血液中的游离脂肪酸(FFA)和存储于肌肉内的甘油三酸酯(intra-muscular triglyceride,IMTG)转化为能量,就必须将其移动到线粒体内。为此,肉毒碱棕榈酰转移酶(CPT-1,carnitinepalmitoyltransferase-1)的活性发挥重要的作用。同时,为了实现β-氧化作用,在将长链脂肪酸运输到线粒体内的过程中,它也发挥着重要的调节作用。
ACC经由5’腺苷酸活化蛋白激酶(AMP-activated protein kinase,AMPK)而被磷酸化及非活性化,上述5’腺苷酸活化蛋白激酶具有可检测细胞能量源变化的机械性作用。当运动时,AMPK的活性增加,这导致ACC被磷酸化,从而活性受到抑制,并且使丙二酸单酰辅酶A(malonyl-CoA)的浓度降低。CPT-1的抑制者即丙二酸单酰辅酶A的减少诱导CPT-1的活性,从而增加流入线粒体内的被酰化(acylate)的脂肪酸。
最近,研发人员正在研究利用植物提取物等副作用小、安全性高的天然物研发一种与上述化学合成品不同的功能性食品。
作为肌肉增加用制剂,韩国专利申请10-2005-709019号中有相应记载。运动能力增强用食品组合物在10-2003-38486号中有记载。另外,符合运动科学的人参制品在10-1997-12503号,运动持续能力提高用饮食组合物在10-2007-104898号中分别均有记载。
本发明的药用植物假荜拔为属于胡椒科(piperaceae family)的植物,是一种生长在东南亚的野生植物,本发明中使用其果实部分。
上述植物传统上常被用作香辛料、调味料、腹部及肠胃疾病的治疗剂和暴露在寒冷的环境时产生生热效果的体温保存剂。假荜拔的氨基化合物(amide)成份含有假荜茇酰胺A(retrofractamide A)、假荜茇酰胺B(retrofractamide B,pipericide)、假荜茇酰胺C(retrofractamide C)、胡椒碱(piperine)、几内亚胡椒酰胺(guineensine)、胡椒酸甲酯(methyl piperate)、墙草碱(pelliorine)、荜拨明宁碱(piperlongumininie)等,并具有抗氧化、抗菌、杀虫效果及提高药物的生物药效率、通过血管扩张产生生热效果等作用。
但是,目前尚未发现本发明中所述的以下效果,即通过UCP活性产生生热作用以减少体重及体脂肪的效果,通过降低空腹血糖及血液中的胰岛素浓度以预防和治疗糖尿病的效果,以及利用AMPK活性抑制ACC和通过增强CPT-1活性促进肌肉量增加与运动量增加的效果。
在本发明中,将生长在东南亚的药用植物中的假荜拔(Piper retrofractumVahl.)果实提取物给诱导肥胖的动物长期摄取后,对其体重及体脂肪量进行测定,发现其指标明显降低,并且,血糖及血液中胰岛素浓度也下降,从而可以确认其具有抗糖尿病的效果。即,连续7周给实验动物给予高脂饮食,诱导其出现肥胖及糖尿病状态后,在8周的时间内投喂假荜拔,结果可以观察到体重及体脂肪减少,同时血液中的糖(glucose)及胰岛素浓度也下降。这一结果表明,假荜拔作为预防和治疗肥胖及糖尿病的治疗剂,可以用作抗肥胖及抗糖尿的功能性食品组合物或药物组合物。
发明内容
技术问题
因此,本发明的目的在于,提供一种以假荜拔(Piper retrofractum Vahl.)果实提取物为有效成份的组合物及含有该提取物的药物组合物。
技术方案
本发明的上述目的需要通过以下几个步骤实现:从假荜拔果实获得提取物的步骤;将上述提取物向肥胖及糖尿病实验鼠投喂进行抗肥胖及抗糖尿病效果与肌肉量及运动能力提升实验,并对其结果进行评估的步骤。
有益效果
依据本发明,含有假荜拔提取物的组合物能够通过减少体重及体脂肪而预防和治疗肥胖,并通过降低血糖及血液中胰岛素浓度而预防糖尿病,同时还能够促进肌肉量增加及运动能力提升。
附图说明
图1是显示在依据本发明的假荜拔提取物处理与否两种情况下,老鼠体重减少的效果。函数图中用**表示的部分是通过单向方差分析(one-wayANOVA)的事后检验即Tukey’s多项比较试验观察到*p<0.05,**p<0.01。
图2是显示在依据本发明的假荜拔提取物处理与否两种情况下,老鼠体脂肪减少的情况。柱形图中用**表示的部分是通过单向方差分析的事后检验即Tukey’s多项比较试验观察到*p<0.05,**p<0.01。
图3是在依据本发明的假荜拔提取物处理与否两种情况下,利用免疫印迹法显示老鼠脂肪细胞(3T3-L1)内UCP3蛋白活性增强与否。
图4是显示在依据本发明的假荜拔提取物处理与否两种情况下,老鼠空腹血糖减少的情况。柱形图中用**表示的部分是通过单向方差分析的事后检验即Tukey’s多项比较试验观察到*p<0.05,**p<0.01。
图5是显示在依据本发明的假荜拔提取物处理与否两种情况下,老鼠空腹胰岛素浓度降低的情况。柱形图中用**表示的部分是通过单向方差分析的事后检验即Tukey’s多项比较试验观察到*p<0.05,**p<0.01。
图6是显示在依据本发明的假荜拔提取物处理与否两种情况下,老鼠的HOMA-IR减少的情况。
图7是在依据本发明的假荜拔提取物处理与否两种情况下,利用免疫印迹法显示老鼠的肝脏内IRS-1蛋白活性增强与否。
图8是在依据本发明的假荜拔提取物处理与否两种情况下,通过老鼠大腿部肌肉的PET/CT扫描图像显示其肌肉的情况。
图9是显示在依据本发明的假荜拔提取物处理与否两种情况下,老鼠大腿部肌肉的体积。柱形图中用**表示的部分是通过单向方差分析的事后检验即Tukey’s多项比较试验观察到**p<0.01。
图10是在依据本发明的假荜拔提取物处理与否两种情况下,将老鼠肌肉内中性脂肪(IMTG)用作能量源显示其含量减少的情况。
图11是在依据本发明的假荜拔提取物处理与否两种情况下,利用踏旋器显示老鼠运动能力增强的效果。柱形图中用*表示的部分是通过单向方差分析的事后检验即Tukey’s多项比较试验观察到*p<0.05。
图12是在依据本发明的假荜拔提取物处理与否两种情况下,利用免疫印迹法显示老鼠肌肉中pAMPK,pACC,CPT-1蛋白活性增强与否。
具体实施方式
含有依据本发明假荜拔提取物的组合物可以通过减少体重及体脂肪而预防及治疗肥胖,并通过降低血糖及血液中胰岛素浓度而预防及治疗糖尿病,同时还可以通过调节作用于更加容易利用肌肉内的能量源的基因(AMPK活性,ACC抑制及CPT-1活性),从而促进肌肉量增加,提升运动能力。
作为本发明的另一实施例,上述假荜拔果实提取物既可以利用有机溶剂萃取,也可以单独利用二氧化碳或者利用二氧化碳和有机溶剂一起采用超临界萃取方式提取。
<实施例>提取方法
将干燥的假荜拔果实粉末与4倍至10倍的萃取溶剂一起放入萃取装置内,放置12小时以上或者进行超临界萃取,然后将其通过浓缩器浓缩并进行干燥处理后获得提取物。
上述萃取溶剂可以使用纯净水(water)、甲醇(methanol)、乙醇(ethanol)、丙醇(propanol)、异丙醇(isopropanol)、丁醇(butanol)、丙酮(acetone)、乙醚(ether)、苯(benzene)、三氯甲烷(chloroform)、乙酸乙酯(ethyl acetate)、二氯甲烷(methylenechloride)、正己烷(hexane)、环己烷(cyclohexane)、石油醚(petroleum ether)或者它们的混合物等多种溶剂,优选地,可以使用乙醇。除此之外,只要适合于将上述假荜拔果实成份作为有效成份进行提取的溶剂均可以使用,并无其它限制。
另外,本发明提供了利用上述组合物的抗肥胖及抗糖尿病的功能性健康食品及药物组合物。由于上述健康食品及药物组合物含有依据本发明的假荜拔果实提取物,因此可以通过人体脂肪细胞的UCP活性机理减少体重及体脂肪而预防及治疗肥胖,并通过降低血糖及血液中胰岛素浓度改善胰岛素抗性(insulin resistance)而预防及治疗糖尿病。另外,即使不刻意运动,也能够通过AMPK活性增强、ACC抑制及CPT-1活性增强使有氧运动的能量供给源的脂肪向肌肉内的线粒体内移动,从而增加肌肉量,并提升运动能力,最终获得运动模拟(mimic)效果。
本发明的抗肥胖的功能性健康食品及药物组合物,如果采用口服,就可以采用本领域公知的方法将其与口服用载体一起制成粉末、颗粒、片剂、丸剂、糖衣片剂、胶囊、液体、凝胶体、糖浆、悬浊液、薄片等多种剂型。适合的载体包括:包括乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖醇、木糖醇、赤藓糖醇及麦芽糖醇等的糖类,包括玉米淀粉、小麦淀粉、大米淀粉及土豆淀粉的淀粉类,包括纤维素、甲基纤维素、羧甲基纤维素钠及羟丙甲纤维素等的纤维素类及类似明胶、聚乙烯吡咯烷酮等填充剂。另外,也可以根据情况将交联聚乙烯基吡咯烷酮、琼胶、藻酸或者褐藻酸钠等作为崩解剂添加。此外,上述药物组合物还可以包括抗凝剂、润滑剂、湿润剂、香料、乳化剂及防腐剂等。
下面,将通过实验例等对本发明进行更加详细的说明。但是,下述实验例等仅是为了对本发明进行说明而列举的示例,它并不限定本发明的权利范围。
[实验例1]测定实验动物的体重及体脂肪
<1-1>实验动物及饲料
在抗肥胖及抗糖尿实验中使用的高脂肪食物为40%脂肪热量,假荜拔提取物按老鼠体重每kg用100mg(EXT100),将5周龄的雄性C57BL/6J老鼠按照高脂肪对照群(HFD群)和根据摄取用量确定的提取物投喂群(EXT群)随意配备后,使它们对实验动物室环境适应1周,对其投喂7周高脂饮食后,在8周内强制投喂赋形剂(Vehicle)或者利用赋形剂分散的提取物。
在运动能力提升实验中使用的高脂肪食物为40%脂肪热量,假荜拔提取物按老鼠体重每kg用100mg(PRE100)或者300mg(PRE300)。将5周龄的雄性C57BL/6J老鼠按照高脂肪对照群(HFD群)和根据摄取用量确定的提取物投喂群2群(PRE100和PRE300群)随意配备后,使它们对实验动物室环境适应1周,给每个实验群的动物均投喂7周高脂饮食后,在8周内强制向它们投喂赋形剂或者利用赋形剂分散的提取物。
<1-2>测定体重及体脂肪
在8周内强制向它们投喂赋形剂或者利用赋形剂分散的萃取物后,测定其死亡之前的体重,死亡后将其附睾脂肪摘出并测定重量[图1与图2]。
[实验例2]测定实验动物的血糖、胰岛素及HOMA-IR
<2-1>测定血糖及胰岛素
在8周内让实验动物摄取本发明的假荜拔果实提取物后,中断饲料供给6小时,切断老鼠尾巴提取少量的血清(serum),并利用该血清测定血糖及胰岛素。实验结果如图4和图5所示,与对照群(HFD)相比,摄取了实验物质即假荜拔提取物的EXT100群的血糖及胰岛素明显减少。
<2-2>测定HOMA-IR
通过上述<2-1>的血糖和胰岛素测定值计算出HOMA-IR值,计算公式如下:
HOMA-IR=FBG(mg.dL)×FI(ng/ml)×0.0717225161669606
如图6所示,假荜拔提取物摄取群与对照群(HFD)相比,摄取了实验物质即假荜拔提取物的EXT100群的HOMA-IR值明显减少,由此可知改善了胰岛素抗性。
[实验例3]评估实验动物的肌肉体积、肌肉脂肪及运动能力提升
<3-1>测定肌肉体积
在8周内让实验动物摄取假荜拔提取物后,利用微型PET/CT(positronemission tomography/Computed tomography,INVEON,Siemens,USA)测定最终肌肉体积,结果如图8和图9所示,与摄取高脂肪食物对照群(HFD)相比,摄取了实验物质即假荜拔提取物的PRE100群和PRE300群的肌肉体积增加了200%。
<3-2>测定肌肉脂肪含量
在8周内让实验动物摄取假荜拔提取物,动物死亡后将肌肉摘出,实施苏木精一伊红染色(H&E)染色,然后观察其脂肪含量。结果如图10所示,与摄取高脂肪食物对照群(HFD)相比,摄取了假荜拔提取物的PRE100群和PRE300群的肌肉脂肪含量明显减少。这是由于存储于肌肉内的甘油三酸酯(intra-muscular triglyceride,IMTG)转换为能量而导致肌肉脂肪含量减少的。
<3-3>评估运动能力提升
在8周内让实验动物摄取假荜拔提取物后,利用踏旋器评估运动能力,按照每分钟11m的速度进行测定,其结果如图4所示,与摄取高脂肪食物对照群(HFD)相比,摄取了假荜拔提取物的PRE100群和PRE300群的运动能力明显增强[图11]。
[实验例4]在实验动物中与抗肥胖、抗糖尿病、运动能力提升相关基因的蛋白质表达增强效果
<4-1>通过热产生与抗肥胖相关基因的蛋白质表达增强效果
对3T3-L1脂肪细胞利用胰岛素、地塞米松、IBMX处理十天左右,使其分化形成脂肪后,再利用假荜拔提取物进行处理,然后再通过免疫印迹法(western blot)确认UCP蛋白质表达[图3],通过α-微管蛋白(α-tublin)表示出各实验样本的蛋白质载量都保持一定的水平。
<4-2>与抗糖尿病相关基因的蛋白质表达增强效果
在8周内让实验老鼠摄取假荜拔果实提取物后,将老鼠的肝脏摘出,通过免疫印迹法(westerm blot)确认IRS-1的蛋白质表达增强[图7],通过α-微管蛋白表示出各实验样本的蛋白质载量都保持一定的水平。
<4-3>与运动能力提升相关基因的蛋白质表达增强效果
在8周内让实验动物摄取假荜拔果实提取物后,将大腿部的肌肉摘出,通过免疫印迹法(westerm blot)确认pAMPK,pACC,CPT-1的蛋白质表达[图12],通过α-微管蛋白表示出各实验样本的蛋白质载量都保持一定的水平。其结果表明,pAMPK,pACC,CPT-1的蛋白质表达量增加。
工业实用性
如上所述,本发明提供了一种源于假荜拔果实提取物的抗肥胖的功能性组合物,特别是,以通过脂肪细胞的UCP活性而产生热量的机理为特征的减少体重及体脂肪的功能性组合物,以降低血糖及血液中胰岛素浓度的机理为特征的胰岛素抗性改善用抗糖尿病的功能性组合物,以利用IRS-1活性为特征的胰岛素抗性改善用抗糖尿病的功能性食品及药物组合物。同时,本发明还提供了以通过AMPK活性实现ACC抑制及CPT-1活性增强为特征的肌肉量增加、运动能力提升及疲劳恢复用功能性食品及药物组合物。因此,本发明在保健医药方面有非常广阔的前景。
Claims (18)
1.一种抗肥胖的功能性食品组合物,其特征在于:
其含有药用植物假荜拔(Piper retrofractum Vahl.)果实提取物为有效成份,并具有减少体重及体脂肪的机理。
2.如权利要求1所述的抗肥胖的功能性食品组合物,其特征在于:
上述假荜拔提取物利用有机溶剂萃取或者采用超临界萃取方式提取果实粉末。
3.一种抗肥胖的药物组合物,其特征在于:
其含有假荜拔果实提取物为有效成份,并具有通过脂肪细胞的UCP活性产生热量的机理。
4.如权利要求3所述的抗肥胖的药物组合物,其特征在于:
上述组合物是一种具有减少体重及体脂肪机理的抗肥胖的保健药用辅助品。
5.如权利要求3所述的抗肥胖的药物组合物,其特征在于:
上述假荜拔果实提取物相对于组合物的总重量计,其含量为0.001重量%至80重量%,并具有减少体重及体脂肪的机理。
6.一种抗肥胖的功能性食品组合物,其特征在于:
上述权利要求1所述的组合物为粉末、颗粒、片剂、胶囊、糖浆或者饮料中的任意一种形态,并具有通过脂肪细胞的UCP活性产生生热作用而减少体重及体脂肪的机理。
7.一种改善胰岛素抗性的抗糖尿病的功能性食品组合物,其特征在于:
其含有药用植物假荜拔果实提取物为有效成份,并具有降低血糖和血液中胰岛素浓度的机理。
8.如权利要求7所述的改善胰岛素抗性的抗糖尿病的功能性食品组合物,其特征在于:
上述假荜拔提取物利用有机溶剂萃取或者采用超临界萃取方式提取果实粉末。
9.一种改善胰岛素抗性的抗糖尿病的药物组合物,其特征在于:
其含有假荜拔果实提取物为有效成份,并具有IRS-1活性机理。
10.如权利要求9所述的改善胰岛素抗性的抗糖尿病的药物组合物,其特征在于:
上述组合物是一种具有降低血糖和血液中胰岛素浓度机理的改善胰岛素抗性的抗糖尿病的保健药用辅助品。
11.如权利要求9所述的改善胰岛素抗性的抗糖尿病的药物组合物,其特征在于:
上述假荜拔果实提取物相对于组合物的总重量计,其含量为0.001重量%至80重量%,并具有降低血糖和血液中胰岛素浓度的机理。
12.一种改善胰岛素抗性的抗糖尿病的功能性食品组合物,其特征在于:
上述权利要求7所述的组合物为粉末、颗粒、片剂、胶囊、糖浆或者饮料中的任意一种形态,并具有降低血糖和血液中胰岛素浓度的机理。
13.一种健康功能性食品组合物,其特征在于:
其含有药用植物假荜拔果实提取物为有效成份,并具有促进肌肉量增加、提升运动能力及恢复疲劳的机理。
14.如权利要求13所述的健康功能性食品组合物,其特征在于:
上述假荜拔提取物利用有机溶剂萃取或者采用超临界萃取方式提取果实粉末。
15.一种药物组合物,其特征在于:
其含有假荜拔果实提取物为有效成份,并具有AMPK活性机理。
16.如权利要求15所述的药物组合物,其特征在于:
上述组合物能促进肌肉量增加、提升运动能力及恢复疲劳。
17.如权利要求15所述的药物组合物,其特征在于:
上述假荜拔果实提取物相对于组合物的总重量计,其含量为0.001重量%至80重量%,并具有促进肌肉量增加、提升运动能力及恢复疲劳的机理。
18.一种健康功能性食品组合物,其特征在于:
上述权利要求13所述的组合物为粉末、颗粒、片剂、胶囊、糖浆或者饮料中的任意一种形态,并具有促进肌肉量增加、提升运动能力及恢复疲劳的机理。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410842636.0A CN104547059B (zh) | 2011-05-31 | 2012-05-31 | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0052190 | 2011-05-31 | ||
KR1020110052191A KR101476761B1 (ko) | 2011-05-31 | 2011-05-31 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만용 조성물 |
KR1020110052190A KR20120133515A (ko) | 2011-05-31 | 2011-05-31 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항당뇨용 조성물 |
KR10-2011-0052191 | 2011-05-31 | ||
KR1020110053484A KR101309849B1 (ko) | 2011-06-02 | 2011-06-02 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 근육량 증대 및 운동력 향상용 조성물 |
KR10-2011-0053484 | 2011-06-02 | ||
PCT/KR2012/004325 WO2012165888A2 (ko) | 2011-05-31 | 2012-05-31 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만, 항당뇨 및 근육량 증대및 운동력 향상용 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410842636.0A Division CN104547059B (zh) | 2011-05-31 | 2012-05-31 | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103717229A true CN103717229A (zh) | 2014-04-09 |
Family
ID=47260097
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410842636.0A Active CN104547059B (zh) | 2011-05-31 | 2012-05-31 | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 |
CN201280027034.9A Pending CN103717229A (zh) | 2011-05-31 | 2012-05-31 | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410842636.0A Active CN104547059B (zh) | 2011-05-31 | 2012-05-31 | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20140186473A1 (zh) |
JP (2) | JP2014516983A (zh) |
CN (2) | CN104547059B (zh) |
HK (1) | HK1204566A1 (zh) |
WO (1) | WO2012165888A2 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109381462A (zh) * | 2018-12-13 | 2019-02-26 | 中国科学院新疆理化技术研究所 | 一种荜茇酰胺类生物碱的降糖用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008069121A (ja) * | 2006-09-15 | 2008-03-27 | Lion Corp | 脂肪減少促進剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3645608B2 (ja) * | 1995-03-10 | 2005-05-11 | 花王株式会社 | 脂肪分解促進剤 |
JP2000136141A (ja) * | 1998-10-30 | 2000-05-16 | Sumitomo Forestry Co Ltd | 抗菌剤 |
JP2002138045A (ja) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | 前駆脂肪細胞分化誘導剤 |
JP2004002267A (ja) * | 2002-03-28 | 2004-01-08 | Kobayashi Pharmaceut Co Ltd | コラゲナーゼ阻害剤及びその利用 |
CA2505140A1 (en) * | 2002-10-29 | 2004-05-21 | Council Of Scientific And Industrial Research | New alpha-glucosidase inhibitors from a natural source |
CN100356940C (zh) * | 2004-12-01 | 2007-12-26 | 蒋毅 | 制备大叶蒟提取物的方法、提取物及其应用 |
JP2007131568A (ja) * | 2005-11-09 | 2007-05-31 | Nippon Seiyaku Kogyo Kk | 免疫賦活剤及びこれを含有する免疫賦活性飲食物 |
KR100805745B1 (ko) * | 2006-10-27 | 2008-02-21 | 한국생명공학연구원 | 비만 또는 제2형 당뇨병의 예방 또는 치료용 조성물 |
JP2011073973A (ja) * | 2009-09-29 | 2011-04-14 | Shiseido Co Ltd | 更年期のための疲労改善組成物 |
-
2012
- 2012-05-31 US US14/122,752 patent/US20140186473A1/en not_active Abandoned
- 2012-05-31 JP JP2014513442A patent/JP2014516983A/ja active Pending
- 2012-05-31 CN CN201410842636.0A patent/CN104547059B/zh active Active
- 2012-05-31 CN CN201280027034.9A patent/CN103717229A/zh active Pending
- 2012-05-31 WO PCT/KR2012/004325 patent/WO2012165888A2/ko active Application Filing
-
2015
- 2015-05-29 HK HK15105136.7A patent/HK1204566A1/zh unknown
-
2016
- 2016-03-09 JP JP2016045156A patent/JP6255432B2/ja active Active
-
2017
- 2017-02-15 US US15/433,552 patent/US20170209511A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008069121A (ja) * | 2006-09-15 | 2008-03-27 | Lion Corp | 脂肪減少促進剤 |
Non-Patent Citations (1)
Title |
---|
DWPI: "ID10104S", 《DWPI_德温特世界专利库》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012165888A3 (ko) | 2013-05-16 |
JP2016165282A (ja) | 2016-09-15 |
HK1204566A1 (zh) | 2015-11-27 |
CN104547059A (zh) | 2015-04-29 |
US20140186473A1 (en) | 2014-07-03 |
US20170209511A1 (en) | 2017-07-27 |
JP6255432B2 (ja) | 2017-12-27 |
WO2012165888A9 (ko) | 2013-03-28 |
WO2012165888A2 (ko) | 2012-12-06 |
JP2014516983A (ja) | 2014-07-17 |
CN104547059B (zh) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tarazona-Díaz et al. | Watermelon juice: potential functional drink for sore muscle relief in athletes | |
CN101890040B (zh) | 一种具有抗疲劳作用的组合物及其应用 | |
US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN108095113A (zh) | 一种具有减脂降糖作用的组合物、制剂及其应用 | |
CN102526479A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN101129441B (zh) | 红景天胶囊及其制备方法 | |
CN105725187B (zh) | 一种降血糖组合物及其用于制备食品和保健食品的用途 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
CN104543662B (zh) | 一种降糖鸡腿菇多糖颗粒的生产方法 | |
KR20130134882A (ko) | 혈당강하에 효능이 있는 돼지감자 및 꾸지뽕잎의 복합추출물 및 이를 이용한 건강기능식품 조성물 | |
CN103717229A (zh) | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 | |
CN108653298A (zh) | 单糖组合物、药物制剂及其应用 | |
CN108323762B (zh) | 一种富硒组合物及制剂,其制备方法和应用 | |
CN101143203A (zh) | 一种具有护肝养胃功能的复方口服液 | |
CN110393249A (zh) | 一种菊苣百合复合固体饮料制品及其制备方法 | |
TWI294284B (zh) | ||
CN102266051A (zh) | 一种抗疲劳的组合物及其制备方法 | |
US20070092587A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
CN107582782A (zh) | 一种含槟榔成分的药物制备方法及其抗缺氧应用 | |
CN102524790B (zh) | 一种药食两用的降糖系列食品及其制备方法 | |
CN101124990A (zh) | 葎草在制备抗疲劳、耐缺氧药物或保健食品中的新用途 | |
CN101505778B (zh) | 含有来自金合欢属树皮的物质的降血糖组合物 | |
CN117770446A (zh) | 一种运动后促恢复的营养组合物及其制备方法和应用 | |
CN104095178A (zh) | 一种辅助降血糖的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140409 |